As a class of drugs specifically targeted to tumors, TROP2-targeted therapeutics are widely regarded as poised to transform the future of solid tumor therapy, such as gastric cancer, pancreatic cancer, breast cancer, prostate cancer (58–61). This evidence concerns the gene TACSTD2 and breast carcinoma.